论文部分内容阅读
目的 评价哌拉西林钠 /舒巴坦钠的体内外抗菌活性。方法 琼脂二倍稀释法测定两药不同配比对临床分离菌最低抑菌浓度 (MIC)值及对产β-内酰胺酶耐药菌感染小鼠的体内保护作用。结果 335株细菌体外实验显示 :哌拉西林钠 /舒巴坦钠 (2∶ 1)较哌拉西林钠单用对产酶耐药株的抗菌活性增强 1～ 4倍以上 ,也增强了哌拉西林钠对革兰阴性菌的抗菌活性。体内试验显示 :哌拉西林钠 /舒巴坦钠 (2∶ 1)及其组分哌拉西林钠、舒巴坦钠及阿莫西林钠 /舒巴坦钠 (2∶ 1)对产酶的金葡菌、大肠埃希菌、肺炎克雷伯菌及铜绿假单胞菌感染小鼠经静脉注射、皮下注射两种给药途径的体内抗菌作用比较 ,哌拉西林钠静脉注射单用对四种菌感染小鼠的 ED50 分别为5 5 .71mg/ kg、6 .5 4 m g/ kg、2 4 .0 9mg/ kg与 11.0 7m g/ kg;哌拉西林钠 /舒巴坦钠 (2∶ 1)者为 2 7.96 mg/ kg、2 .4 9mg/ kg、6 .75 mg/ kg与 6 .36 mg/ kg,分别比哌拉西林钠强 2、2 .5、3.5与 1.8倍。哌拉西林钠 /舒巴坦钠 (2∶ 1)对产酶的革兰阴性菌静脉注射的体内抗菌活性强于对革兰阳性菌者。哌拉西林钠 /舒巴坦钠 (2∶ 1)皮下注射对四种产酶菌感染小鼠的保护作用弱于静脉注射者。结论 哌拉西林钠 /舒巴坦钠对产酶耐药株的抗菌活性强于哌拉西林钠单用 ,无论静?
Objective To evaluate the antibacterial activity of piperacillin sodium / sulbactam sodium in vitro and in vivo. Methods Agar double dilution method was used to determine the minimum inhibitory concentration (MIC) value of different combinations of two drugs in clinical isolates and the in vivo protective effect on β-lactamase-resistant bacterial infection in mice. Results 335 bacteria in vitro experiments showed that piperacillin sodium / sulbactam sodium (2 1) than piperacillin sodium single antibacterial activity of the enzyme-resistant strains increased more than 1 to 4 times, but also enhance the piperazine Antibacterial Activity of Xilin Sodium Against Gram Negative Bacteria. In vivo tests showed that piperacillin / sulbactam sodium (2: 1) and its components piperacillin sodium, sulbactam sodium and amoxicillin sodium / sulbactam sodium (2: 1) Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa infection in mice by intravenous injection, subcutaneous injection of two routes of administration in vivo antibacterial effect compared with intravenous piperacillin sodium single four The ED50 of the inoculum-infected mice were 55.71 mg / kg, 6.44 mg / kg, 24.0 9 mg / kg and 11.0 7 mg / kg, respectively. Piperacillin sodium / sulbactam sodium (2: 1) were 2 7.96 mg / kg, 2.49 mg / kg, 6.75 mg / kg and 6 .36 mg / kg respectively, which were 2.2, 3.5, 3.5 and 1.8 times stronger than piperacillin respectively. Piperacillin sodium / sulbactam sodium (2: 1) was more active against Gram-positive bacteria than Gram-negative bacteria in vivo. Piperacillin sodium / sulbactam sodium (2 1) subcutaneous injection of four strains of mice infected with enzyme-producing mice weaker than intravenous injection. Conclusion The antibacterial activity of piperacillin sodium / sulbactam sodium to drug-resistant strains is stronger than piperacillin sodium alone,